Vicus Capital Repligen Corp Transaction History
Vicus Capital
- $1.09 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding RGEN
# of Institutions
522Shares Held
53.2MCall Options Held
1.05MPut Options Held
228K-
Black Rock Inc. New York, NY7.77MShares$939 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.1MShares$616 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.57MShares$431 Million0.08% of portfolio
-
State Street Corp Boston, MA1.76MShares$212 Million0.01% of portfolio
-
Macquarie Group LTD Australia, C31.46MShares$177 Million0.31% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $6.7B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....